Therefore, it is similar in principle to the approved CAR T-cell therapies used in cancer therapy, such as Kymriah and ...

Gilead subsidiary Kite has been a pioneer in the autologous CAR T-cell therapy space. The drugmaker markets Yescarta ...

The inMIND trial results have elevated expectations for Monjuvi's commercial success, but competition is on the horizon.

This early data has demonstrated a clear improvement in GLPG5101 efficacy over its competitors in iNHL and MCL.

These long-term data support axicabtagene ciloleucel as a highly effective therapeutic approach for patients with relapsed or ...

Gilead Sciences presents five-year Phase II ZUMA-5 trial results for Yescarta in relapsed non-Hodgkin lymphomas, showing a 90 ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

Kite unit reported positive results from a five-year follow-up of a Phase 2 study for its cell therapy Yescarta in certain ...

Kite, a Gilead Company, announced results from a five-year follow-up analysis of ZUMA-5, a Phase 2 study of Yescarta in patients with relapsed/refractory no ...

Lymphoma patients better tolerated the CAR T-cell therapy manufactured on site at the Sheba Medical Center than they did the ...

GlobalData’s analysts predict $158 million in global sales for AZD0486 by 2030, with $2.4 billion for Epkinly and $949 million for Lunsumio.

Johnson & Johnson today announced new frontline data featuring TECVAYLI® (teclistamab-cqyv) from two investigational studies in patients with newly diagnosed multiple myeloma (NDMM) in induction and ...